Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600600 · ClinicalTrials.gov registry record · Phase 2
Tigecycline for Treatment of Rapidly Growing Mycobacteria
A Phase 2 study, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00600600: Completed Phase 2 study, sponsored by The University of Texas Health Science Center at Tyler.
NCT00600600 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600600, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
Primary Outcome
culture neg X3 ( sputum conversion)
Interventions
- DRUG Tigecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00600600 record still lists
NCT00600600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Tigecycline is the first listed.
NCT00600600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00600600 about?
NCT00600600 is a clinical study titled "Tigecycline for Treatment of Rapidly Growing Mycobacteria". To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
What is the current status of trial NCT00600600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2002-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00600600?
The interventions under investigation include: Tigecycline (DRUG).
Who is sponsoring clinical trial NCT00600600?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00600600's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia